Advertisement

Pulmonology General

Invasive Aspergillosis (IA): Clinical and Radiologic Characteristics

Jul 14, 2022

Invasive aspergillosis (IA) is a dangerous consequence that is difficult to identify in immunocompromised and critically sick individuals. For a study, researchers sought to determine how many instanc...

Medical Thoracoscopy: A Well-Established Diagnostic Method for Pleural Effusions

Jul 14, 2022

In situations of unexplained exudative pleural effusions, medical thoracoscopy (MT) is a well-established diagnostic method. However, despite the benefits of MT, problems exist since cancers may resem...

Patients with Cystic Fibrosis (CF) Are Not Eligible for Highly Effective Modulator Therapies

Jul 14, 2022

The availability of mutation-specific cystic fibrosis modulator medicines has the potential to enhance the lives of cystic fibrosis patients, both children and adults. The prevalence of mutations that...

Occupational Therapy in Pulmonary Rehabilitation Programs

Jul 14, 2022

The cornerstone of chronic respiratory illness care is pulmonary rehabilitation (PR), a multidisciplinary strategy that improves persons' exercise capacity and skills to fulfill activities of daily li...

Clinical and Genetic Epidemiology for Human Parainfluenza 2 and 4

Jul 13, 2022

For a study, researchers sought to understand that about 4 members of the genetically separate genera, Respirovirus (HPIV1&3) and Orthorubulavirus (HPIV2&4), make up the human parainfluenza vi...

SARS-CoV-2 and Household Transmission Investigations

Jul 13, 2022

In studies in line with the WHO Unity Studies Household Transmission Investigations (HHTI) protocol, researchers aimed to calculate the household secondary infection attack rate (hSAR) of SARS-CoV-2. ...

Anxiety & Depression in COPD Not Adequately Treated

Jun 20, 2022

Anxiety and depressive symptoms, although common in patients with COPD, are not frequently assessed, identified, and treated in this patient population. “Comorbid anxiety and depressive sympt...

Medical Comorbidities & Lung Cancer Screening

Jun 16, 2022

For a study, researchers looked at the prevalence and consequences of comorbidities in a real-world population of people getting LDCT scans. In an integrated safety-net healthcare system, they estimat...

Concurrent High PD-L1 Expression & CD8+ IC Infiltration: PD-1 Blockade Efficacy

Jun 16, 2022

Patient features, PD-L1 expression, and immune cell (IC) status in the tumor microenvironment (TME) were explored to see if they were linked to PD-1 blocking therapeutic outcomes. Between January 2016...

Ground-Glass Opacity Predominant Lung Cancer After SBRT

Jun 16, 2022

For a study, researchers sought to assess GGOp-LC early-phase CT findings following SBRT. Patients with GGOp-LC staged as cTis-2bN0M0 who received SBRT were identified retrospectively. Radiologists' i...

Concurrent Chemoradiotherapy, Followed By Pembrolizumab for Limited-Stage Lung Cancer

Jun 13, 2022

Even if an initial response was obtained, the prognosis remains poor due to small-cell lung cancer (SCLC's) aggressiveness and the high likelihood of progression or relapse. As a result, the populatio...

FeNO Testing Effective as Diagnostic Tool in Urban Setting

Jun 08, 2022

Initial and consistent fractured exhaled nitric oxide measurements can help identify asthma-related morbidity in children living in urban areas.   Asthma affects every age group, gender, ra...

Quality of life (QOL) in Octogenarians After Lung Resection

Jun 08, 2022

For a study, researchers sought to compare patients aged less than 80 to patients aged more than or equal to 80 in terms of postoperative outcome and quality of life (QOL). QoL was assessed in patient...

Tepotinib Safety & Management: MET Exon 14 Skipping NSCLC

Jun 08, 2022

Researchers thoroughly analyzed adverse events of clinical interest (AECIs) in the VISION trial, including edoema, a MET inhibitor class effect. For patients with MET Exon 14 skipping NSCLC in the pha...

Emibetuzumab With Erlotinib & Emibetuzumab Monotherapy

Jun 08, 2022

For a study, researchers sought to see if emibetuzumab + erlotinib could overcome acquired resistance to erlotinib in MET protein-positive NSCLC patients enriched for EGFRmt. Patients with Stage IV NS...

Complex Segmentectomy vs. Wedge Resection: NSCLC

Jun 08, 2022

Using a large cohort, multicenter database, and propensity score-matched analysis, researchers evaluated the oncological outcomes of complex segmentectomy and wedge resection for clinical stage 0-IA l...

EGFR-Mutated Non-Small Cell Lung Cancer & Leptomeningeal Disease

Jun 08, 2022

The natural history of this disease and the best systemic therapy options were unknown, especially in the era of osimertinib. Researchers found 54 patients with EGFR-mutated NSCLC with LM illness trea...

Pembrolizumab & Concurrent Chemoradiotherapy for Stage III NSCLC (KEYLYNK-012)

Jun 08, 2022

In the absence of disease progression, durvalumab was an approved treatment option after concomitant chemoradiotherapy. The KEYLYNK-012 study was a multicenter, phase III, randomized, placebo- and act...

First-line Pembrolizumab-Based Therapy: Clinical Biomarkers Impact

Jun 08, 2022

Between 2014 and 2019, researchers conducted a retrospective 3-center analysis using electronic medical record data for patients with stage IV NSCLC. The latter were treated with pembrolizumab as firs...

Comorbidities' Impact on Lung Cancer Screening Evaluation

Jun 08, 2022

The impact of self-reported chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), stroke, and diabetes mellitus (DM) on diagnostic difficulties in lung cancer screening was inve...